<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rabies immune globulin and vaccine</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rabies immune globulin and vaccine</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Rabies immune globulin and vaccine</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Brown, DVM, MSc, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alfred DeMaria, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>More than 3.3 billion people worldwide live in areas where rabies is enzootic. Human mortality from rabies is estimated at 59,000 deaths per year. Most cases occur in Africa and Asia and result primarily from canine reservoirs of rabies virus [<a href="#rid1">1</a>]. In the United States, an average of three fatal human rabies cases have occurred annually since 2000, and almost 25 percent of those were imported cases due to exposures occurring abroad; among the 75 percent acquired within the United States, most have been associated with exposure to bats [<a href="#rid2">2,3</a>].</p><p>Rabies is virtually always fatal, but infection can be prevented with proper wound care and prompt post-exposure prophylaxis. Pre-exposure prophylaxis may also prevent rabies but is not a replacement for wound care and post-exposure prophylaxis. In the United States, approximately 16,000 to 39,000 patients with contact to potentially rabid animals receive rabies post-exposure prophylaxis annually [<a href="#rid4">4,5</a>].</p><p>The safety, efficacy, and administration of <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> and <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> will be reviewed here. Clinical decision-making regarding the necessity for rabies post-exposure and pre-exposure prophylaxis can be complex and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis"</a> and  <a class="medical medical_review" href="/z/d/html/139471.html" rel="external">"Rabies pre-exposure prophylaxis"</a>.)</p><p class="headingAnchor" id="H636145644"><span class="h1">RABIES BIOLOGICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">Rabies vaccine</a> and <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> (RIG) are administered to prevent rabies. Several formulations are available and are described in this section. Additional information on choice of regimen and dosing schedules are discussed in detail below. (See <a class="local">'Pre-exposure prophylaxis'</a> below and <a class="local">'Post-exposure prophylaxis'</a> below.)</p><p class="headingAnchor" id="H793098785"><span class="h2">Rabies vaccines</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">Rabies vaccine</a> is administered for pre- or post-exposure prophylaxis. The dosing schedule is determined by the intended use and whether the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid4">4,6</a>] or the World Health Organization (WHO) [<a href="#rid7">7</a>] guidelines, or other local guidelines, represent the standard of care in the jurisdiction.</p><p>Rabies vaccines should be administered intramuscularly (IM) in doses of 1 mL according to the recommended schedules for pre- or post-exposure prophylaxis  (<a class="graphic graphic_table graphicRef74185" href="/z/d/graphic/74185.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>). The suggested anatomic sites for vaccine administration depend on the age of the patient [<a href="#rid4">4,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In adults (ie, age ≥19 years), the deltoid muscle of the arm is the only acceptable IM site of vaccine administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children 3 to 18 years old, the deltoid muscle of the arm is preferred, although the anterolateral aspect of the thigh is an acceptable alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children ≤2 years old, the anterolateral aspect of the thigh is preferred; however, in children aged 12 months to 2 years, the deltoid muscle of the arm is an acceptable alternative if the deltoid muscle mass is adequate.</p><p></p><p>Vaccine should <strong>never</strong> be administered in the gluteal area because this may result in lower antibody titers [<a href="#rid9">9</a>].</p><p>Two licensed, inactivated virus vaccines are currently available in the United States:</p><p class="bulletIndent1"><span class="glyph">●</span>Human diploid cell vaccine (HDCV; Imovax Rabies)</p><p class="bulletIndent1"><span class="glyph">●</span>Purified chick embryo cell vaccine (PCECV; RabAvert)</p><p></p><p>Rabies vaccines available outside the United States include the following: PCECV (Rabipur), HDCV (Rabivac), purified Vero cell <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> (PVRV; Verorab; Imovax-Rabies Vero, Rabivax-S, TRC Verorab) and purified duck embryo vaccine (Lyssavac N). In resource-limited countries, PVRV and PCECV are most commonly used because they are less expensive and are as safe and effective as HDCV [<a href="#rid10">10</a>]. However, their cost is still too high for many resource-limited countries given the frequency of post-exposure prophylaxis that is needed.</p><p>To reduce costs, WHO guidelines include recommendations for a reduced-dose intradermal regimen [<a href="#rid11">11,12</a>]. Intradermal administration is not an approved route of administration for patients receiving a <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> in the United States. More detailed discussions of intradermal regimens are found elsewhere. (See <a class="local">'Pre-exposure prophylaxis'</a> below and <a class="local">'Resource-limited settings'</a> below.)</p><p>Some countries have produced vaccine in sheep, goat, or suckling mouse nervous tissue to reduce costs, but these vaccines have unreliable potency and a high incidence of neurologic complications [<a href="#rid13">13</a>]. There is an international effort to eliminate such products [<a href="#rid14">14</a>].</p><p>Experimental vaccines are under investigation, such as a rabies messenger RNA vaccine. In a phase I trial that included 101 healthy adults, this vaccine was generally found to be safe and immunogenic when administered with a needle-free device [<a href="#rid15">15</a>]. Recombinant virus-vectored rabies vaccines are available in veterinary medicine but not for human use. Although these novel vaccines may offer a pathway to more robust and durable immune responses and possibly single-dose post-exposure prophylaxis, it will be challenging to conduct studies evaluating their efficacy compared with currently available vaccines that have proven to be highly effective in preventing fatal disease.</p><p class="headingAnchor" id="H1978327588"><span class="h2">Rabies immune globulin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">Rabies immune globulin</a> (RIG) is administered as part of a post-exposure prophylaxis regimen. RIG is derived from pooled plasma samples of hyperimmunized human donors (human RIG; HRIG) or from horses (equine RIG; ERIG). Both preparations are considered equally potent and effective; however, only HRIG is recommended for use in the United States [<a href="#rid4">4</a>]. Although these products are derived from human donors or horses, they are treated in ways that eliminate other infectious agents, and no transmission of any infections has been documented from either product.</p><p>The recommended dose of HRIG is 20 international units/kg in all age groups (higher doses should be avoided as they may partially suppress antibody response to the vaccine) [<a href="#rid16">16</a>]. Outside the United States, if ERIG is used (including F(ab')2 products), the dose is 40 international units/kg body weight.</p><p>As much of the RIG dose as is anatomically feasible should be infiltrated in the area around and in the wound at the same depth as the wound. Any remaining dose should be given intramuscularly and at a different intramuscular site than the vaccine (such as the opposite deltoid).</p><p>If there is no obvious wound (eg, suspected bat exposure), the entire volume of RIG should be administered intramuscularly, preferably into the anterolateral thigh or the deltoid muscle contralateral to the vaccine dose. In children with small muscle mass, it may be necessary to administer RIG into more than one anatomic site [<a href="#rid17">17</a>]. Injection into the gluteus muscle should be avoided as it carries the risk for sciatic nerve damage.</p><p>Three preparations of HRIG are approved and available for use in the United States  (<a class="graphic graphic_table graphicRef51563" href="/z/d/graphic/51563.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>HyperRAB 300 international units/mL (1 mL, 5 mL); caprylate/chromatography purified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imogam Rabies – HT 150 international units/mL (2 mL, 10 mL); heat treated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>KEDRAB 150 international units/mL (2 mL, 10 mL); solvent/detergent treated [<a href="#rid18">18</a>].</p><p></p><p>The 150 international units/mL formulations should not require dilution; volumes at the recommended dose are often substantial. The Grifols HyperRab 300 international units/mL product should be diluted with <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">5 percent dextrose in water</a> (D5W) rather than <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, if necessary, to provide adequate volume for wound infiltration with careful attention to assure the recommended dose is administered.</p><p>HRIG is also available outside the United States under a variety of trade names including: BayRab, Berirab P, Imogam, and Imogam Rabies. However, imported HRIG is expensive, and generic products (made in some blood banks outside of the United States) are in scarce supply.</p><p>ERIG (ie, equine RIG) is a less expensive but safe and effective alternative for RIG in some resource-limited settings [<a href="#rid10">10,14,19</a>]. Certain ERIG products are available in a more purified form consisting of immunoglobulin cleavage fragments that are more rapidly cleared after administration [<a href="#rid7">7</a>]. Despite the potential advantages of ERIG, during the past two decades several major manufacturers have discontinued ERIG production because of costs, pressures from animal rights activists, and increased requirements of national regulatory authorities [<a href="#rid19">19</a>].</p><p>Due to global shortages of HRIG and ERIG and the expense of production, alternative means of prophylaxis are being sought. Human monoclonal antibodies (CR57 and CR4098) have demonstrated in vitro neutralization against rabies virus and have provided a level of protection similar to HRIG against lethal rabies virus in animal models [<a href="#rid20">20</a>]. In the first clinical study among healthy adults in the United States and India, CR57 and CR4098 were safe and well tolerated [<a href="#rid21">21</a>]. All subjects had adequate neutralizing activity against rabies virus from day 14 onward when administered in combination with <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a>.</p><p>Another neutralizing monoclonal antibody (SII RMAb) has also shown promise and appears safe and noninferior to HRIG in rabies virus neutralizing antibody activity as measured by the rapid fluorescent focus inhibition test [<a href="#rid22">22,23</a>]. In 2016, the first rabies monoclonal antibody product using SII RMAb was licensed for use in India as the passive antibody component of post-exposure prophylaxis.</p><p class="headingAnchor" id="H122975002"><span class="h1">PRE-EXPOSURE PROPHYLAXIS</span><span class="headingEndMark"> — </span>Pre-exposure prophylaxis is the use of <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> to induce at least partial immunity in individuals who are at elevated risk of acquiring rabies. A detailed discussion of the indications and regimens for pre-exposure prophylaxis is found separately. (See  <a class="medical medical_review" href="/z/d/html/139471.html" rel="external">"Rabies pre-exposure prophylaxis"</a>.)</p><p class="headingAnchor" id="H3064587762"><span class="h1">POST-EXPOSURE PROPHYLAXIS</span><span class="headingEndMark"> — </span>Post-exposure prophylaxis includes proper wound care and administration of rabies biologics. A detailed discussion of who should receive post-exposure prophylaxis is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis"</a>.)</p><p>Our approach to post-exposure prophylaxis is based upon guidelines from the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid4">4</a>]. The full set of guidelines can be accessed at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpdf%2Frr%2Frr57e507.pdf&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAYYkdjH6HWdFi7b%2BDaSf7Vb8gxrnWGuqfzY2Yk0HgOtRvOzKYdLxhQ31ScbVRK8fw%3D%3D&amp;TOPIC_ID=8303" target="_blank">www.cdc.gov/mmwr/pdf/rr/rr57e507.pdf</a> (with updated vaccine schedule recommendations from 2010 at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpdf%2Frr%2Frr5902.pdf&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAYYkdjH6HWdFi7b%2BDaSf7X4d5EEafCrIqyi76PuAHrr&amp;TOPIC_ID=8303" target="_blank">www.cdc.gov/mmwr/pdf/rr/rr5902.pdf</a>). These post-exposure guidelines are being reviewed and updated by an Advisory Committee on Immunization Practices (ACIP) workgroup [<a href="#rid24">24</a>].</p><p>Special considerations for post-exposure prophylaxis in resource-limited settings are discussed below. (See <a class="local">'Resource-limited settings'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Wound care</span><span class="headingEndMark"> — </span>The most important initial step to prevent rabies is wound care. Thorough washing of bite wounds, scratches, and nonbite exposures with soap and water is important. When available, a virucidal agent such as povidone-iodine should also be used. Tetanus prophylaxis, as well as antibiotics, should also be considered, depending on the type of wound. (See  <a class="medical medical_review" href="/z/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7671.html" rel="external">"Animal bites (dogs, cats, and other mammals): Evaluation and management"</a>.)</p><p>In animal studies of rabies, wound cleansing alone reduced the likelihood of rabies by up to 90 percent [<a href="#rid25">25</a>]. However, a survey of international travel medicine providers suggested that many of those presenting with wounds from an animal exposure did not perform adequate wound cleaning [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H289177521"><span class="h2">Post-exposure immunization</span><span class="headingEndMark"> — </span>Post-exposure prophylaxis includes <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> (active immunization) with or without <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> (passive immunization). The use of these agents elicits neutralizing antibodies after rabies exposure and prevents infection.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">Rabies vaccine</a> induces the production of protective virus-neutralizing antibodies within approximately 7 to 10 days; measurable antibody generally persists for several years, although individual variability exists [<a href="#rid27">27-29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The administration of <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> (RIG) provides immediate virus-neutralizing antibodies until protective antibodies are generated in response to vaccine. Human RIG (HRIG) has a half-life of approximately three weeks [<a href="#rid16">16</a>]. Virus neutralization is most effective when HRIG is infiltrated into and around the wound; circulating neutralizing antibody levels remain low when it is administered intramuscularly at a site distant from the wound [<a href="#rid30">30</a>]. (See <a class="local">'Rabies immune globulin'</a> above.)</p><p></p><p>The regimen for post-exposure prophylaxis depends primarily upon the patient's previous immunization history. Immunization schedules, doses, and routes of administration are summarized in the table  (<a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>) and discussed in greater detail below. (See <a class="local">'Regimens for unvaccinated individuals'</a> below and <a class="local">'Regimens for previously vaccinated individuals'</a> below.)</p><p>Occasional case reports of rabies in individuals who have received partial rabies post-exposure prophylaxis exist in the literature. (See <a class="local">'Risk of prophylaxis failure'</a> below.)</p><p class="headingAnchor" id="H1595665037"><span class="h3">Timing of immunization</span><span class="headingEndMark"> — </span>Once it has been determined that a patient should receive rabies post-exposure prophylaxis, prophylaxis should begin as soon as possible after the exposure [<a href="#rid31">31</a>]. The decision to initiate prophylaxis requires a thorough risk assessment, which depends upon the type of exposure, the local rabies epidemiology, the circumstances of the exposure incident, and the availability of the animal for observation or rabies testing  (<a class="graphic graphic_algorithm graphicRef71322" href="/z/d/graphic/71322.html" rel="external">algorithm 1</a>) [<a href="#rid4">4</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis", section on 'Evaluating the source of exposure'</a>.)</p><p>Post-exposure prophylaxis should be administered following a rabies exposure, even if there is a delay; post-exposure prophylaxis is only too late when signs of clinical rabies develop. The average incubation period is 45 days but is highly variable; latency periods between exposure and onset of disease as long as one to eight years have been reported [<a href="#rid32">32,33</a>]. No post-exposure prophylaxis failures have been reported in the United States despite an average delay to initiation of approximately five days. Nonetheless, every effort should be made to administer post-exposure prophylaxis as soon as possible following a rabies exposure, unless the animal is available for observation or testing.</p><p>State and local public health officials are available to assist with risk assessments in the United States, and contacts can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Frabies%2Fresources%2Fcontacts.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP34avy7K48jfK0PvxCnCh3r9Biz1uu56%2BYn0IY7HtcwZl6JErfqwi8KMF%2FrvK5VwQ%3D%3D&amp;TOPIC_ID=8303" target="_blank">Centers for Disease Control and Prevention website</a>.</p><p class="headingAnchor" id="H3510084102"><span class="h3">Regimens for unvaccinated individuals</span><span class="headingEndMark"> — </span>For patients who have not been previously vaccinated, post-exposure prophylaxis should always include both passive and active immunization  (<a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>).</p><p>Studies that have evaluated the efficacy of RIG plus vaccine include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The combination of five intramuscular (IM) doses of human diploid cell vaccine (HDCV) and HRIG prophylaxis was evaluated in 90 persons treated after exposure to rabies, 21 of whom were bitten by proven rabid animals [<a href="#rid27">27</a>]. All 87 persons tested developed protective titers of antibody (≥0.5 international units/mL). One year after vaccination, all 33 persons who had follow-up testing had detectable antibodies to rabies virus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Forty-five persons bitten by rabid dogs and wolves in Iran were treated with HDCV, and all except one also received RIG [<a href="#rid34">34</a>]. None of the exposed persons developed rabies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 40 patients with rabies exposure treated with HDCV, all patients seroconverted regardless of whether they received RIG. However, those who received both had significantly higher rabies antibody titers [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study reported no human rabies cases among 45 patients receiving six intramuscular doses of purified chick embryo cell vaccine (PCECV) and HRIG after being exposed to biopsy-proven rabid animals [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Chinese study of 171 patients with severe rabies exposure who received five IM purified Vero cell <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> (PVRV) plus equine RIG (ERIG) demonstrated protective neutralizing antibodies of more than 0.5 international units/mL by day 14 in all 171 cases. No one developed rabies up to six months after treatment [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H20"><span class="h4">Rabies immune globulin administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">Rabies immune globulin</a> should be administered at the same time as the initial dose of vaccine (day 0) to patients who have <strong>not</strong> received a <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> series in the past. It is also required for some patients who have received prior rabies vaccination. (See <a class="local">'Vaccine schedule for unvaccinated persons'</a> below and <a class="local">'Vaccine schedule for previously vaccinated persons'</a> below.)</p><p>RIG should always be given in a different syringe from the vaccine. Additional details regarding administration of RIG are found in the table  (<a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>) and described above. (See <a class="local">'Rabies immune globulin'</a> above.)</p><p>The use of RIG in patients who have a potential rabies exposure during (ie, before completing) a pre-exposure vaccine series, as well as in those who have initiated a post-exposure vaccination regimen without receiving immediate RIG, is discussed below. (See <a class="local">'Regimens for previously vaccinated individuals'</a> below and <a class="local">'Deviations from immunization regimens'</a> below.)</p><p class="headingAnchor" id="H749927992"><span class="h4">Vaccine schedule for unvaccinated persons</span><span class="headingEndMark"> — </span>After a rabies exposure, immunocompetent patients should receive <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> starting promptly after exposure (day 0) and on days 3, 7, and 14  (<a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>) [<a href="#rid38">38,39</a>]. Additional information regarding timing and administration of the vaccine is described above. (See <a class="local">'Timing of immunization'</a> above and <a class="local">'Rabies vaccines'</a> above.)</p><p>For immunocompromised hosts, a fifth dose on day 28 should be administered. In addition, such patients should have an antibody titer checked 7 to 14 days after the final dose to assess their response (see <a class="local">'Postvaccination serologic testing'</a> below). Although data are limited, corticosteroids, other immunosuppressive drugs and biologic agents, and immunocompromising illnesses may prevent the immune response to rabies vaccination to the point of insufficient neutralizing antibody [<a href="#rid40">40-42</a>].</p><p>Earlier guideline recommendations had included a fifth dose of <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> on day 28 for all patients, which is consistent with the package inserts from both manufacturers that provide vaccine in the United States (Bavarian Nordic and Sanofi Pasteur) [<a href="#rid38">38</a>]. The decision to reduce the regimen to a four-dose series for immunocompetent patients is based upon global epidemiologic studies, which found that rabies did not develop in any patient who received appropriate wound care, HRIG, and four doses of vaccine; in addition, immunologic studies found the fifth dose did not lead to a further increase in antibody titers [<a href="#rid38">38,43,44</a>].</p><p>Reducing the number of clinic visits for rabies prophylaxis can help improve completion of post-exposure dosing schedules, especially in areas where access to medical care is limited and requires significant travel. Preliminary results from one study in healthy volunteers suggest that a one-week schedule of prophylaxis increases neutralizing antibody levels compared with standard regimens [<a href="#rid45">45</a>], although this has not been adopted by either the CDC or the World Health Organization (WHO).</p><p class="headingAnchor" id="H24"><span class="h3">Regimens for previously vaccinated individuals</span><span class="headingEndMark"> — </span>Some previously vaccinated individuals require only two vaccine doses after an exposure, whereas others require a full four-dose series and RIG despite having received prior vaccination.</p><p class="headingAnchor" id="H3682597385"><span class="h4">Criteria for a two-dose post-exposure vaccination series</span><span class="headingEndMark"> — </span>Patients who report having received a prior three-dose pre-exposure prophylaxis series or a prior post-exposure series of ≥4 doses and were immunocompetent at the time of the prior vaccinations require only two booster doses for post-exposure prophylaxis. If they were immunocompromised at the time of their prior vaccinations, they must also have had at least one titer that showed a result of ≥0.5 international units/mL.</p><p>Additional situations for which only two vaccine doses are necessary for post-exposure prophylaxis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Completion of at least two doses of a pre-exposure prophylaxis series within the three years prior to the exposure. Persons who were immunocompromised at the time of their pre-exposure vaccination series must also have had at least one titer that showed a result of ≥0.5 international units/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior partial completion of a pre- or post-exposure vaccination series <strong>and</strong> at least one titer check that showed a result of ≥0.5 international units/mL.</p><p></p><p>All prior vaccine doses must have been given after the advent of modern vaccines (PCECV, HDCV, or PVRV), which became available in the United States in the early 1980s.</p><p>For certain previously vaccinated patients, we suggest consultation with local or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Frabies%2Fresources%2Fcontacts.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP34avy7K48jfK0PvxCnCh3r9Biz1uu56%2BYn0IY7HtcwZl6JErfqwi8KMF%2FrvK5VwQ%3D%3D&amp;TOPIC_ID=8303" target="_blank">state public health authorities</a> to determine the most appropriate post-exposure regimen:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who became immunocompromised after their last positive titer check </p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose exposure occurred in the midst of (or &lt;21 days after) a two-dose pre-exposure prophylaxis series</p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose prior vaccines were not derived from cell-culture or chick-embryo</p><p></p><p class="headingAnchor" id="H2295393811"><span class="h4">Vaccine schedule for previously vaccinated persons</span><span class="headingEndMark"> — </span>For individuals who meet the above criteria for a two-dose postvaccination series, the first dose is administered on day 0 as soon after exposure as possible and the second dose is administered three days later  (<a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>). Both the CDC and the WHO endorse the two-dose post-exposure vaccination series for individuals described above [<a href="#rid4">4,11</a>]. (See <a class="local">'Criteria for a two-dose post-exposure vaccination series'</a> above.)</p><p>RIG is not recommended for individuals who qualify for the two-dose post-exposure series. It is unnecessary in these patients because the anamnestic response to vaccine is sufficiently rapid in persons who were effectively vaccinated previously [<a href="#rid4">4,11</a>].</p><p>For all individuals who don’t qualify for a two-dose post-exposure series, prophylaxis is provided using the same regimen recommended for individuals without any history of prior vaccination (four vaccine doses plus RIG for immunocompetent individuals) [<a href="#rid6">6,11</a>]. (See <a class="local">'Regimens for unvaccinated individuals'</a> above.)</p><p>Additional information regarding administration of the vaccine is found above. (See <a class="local">'Rabies vaccines'</a> above.)</p><p class="headingAnchor" id="H774831324"><span class="h2">Special considerations</span></p><p class="headingAnchor" id="H308831641"><span class="h3">Resource-limited settings</span><span class="headingEndMark"> — </span>While post-exposure prophylaxis can prevent deaths in patients exposed to rabies, the treatment regimen is expensive, costing up to several thousand dollars per person for biologics alone [<a href="#rid46">46</a>]. The annual expenditure for rabies globally has been estimated at USD $8.6 billion in direct costs and lost productivity, with Asia and Africa accounting for the majority. The cost of post-exposure prophylaxis with <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> and vaccine accounts for a significant proportion of this expenditure [<a href="#rid1">1</a>].</p><p>To address these cost-related issues in resource-limited settings, the WHO has developed protocols that include the use of intradermal vaccination regimens and the use of RIG only after select exposures and to the extent that it can be infiltrated into and around the wound. The WHO guidelines are summarized in the table  (<a class="graphic graphic_table graphicRef118695" href="/z/d/graphic/118695.html" rel="external">table 4</a>) [<a href="#rid11">11,12</a>]. More detailed information on the WHO recommendations can be accessed at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fcontrol-of-neglected-tropical-diseases%2Frabies%2Fvaccinations-and-immunization%2F&amp;token=1ReC%2FAJHVuifDlXGC711yhg60dsOH5h61KyOq%2BsQmLB%2BQZ1rIsGGQSra4yBi%2FEDdhMb7OXbCF1OgLcauISMY0id%2FqrHMKCedtPy%2BdIJJBSUxhFQY%2Bb1%2Bl%2BiARmuVzkKu&amp;TOPIC_ID=8303" target="_blank">WHO website</a>.</p><p>In areas where vaccine and financial resources are in short supply, intradermal administration of vaccine can reduce costs by up to 80 percent. The effectiveness of current cell culture vaccines given intradermally with or without RIG among rabies-exposed humans has been demonstrated in several studies with different schedules [<a href="#rid47">47-50</a>].</p><p>For United States travelers who received post-exposure prophylaxis in a resource-limited setting, receipt of the complete series of vaccine by the intradermal method may be sufficient, and documentation of antibody titer response may be used to assure the expected level of neutralizing antibody. (See <a class="local">'Postvaccination serologic testing'</a> below.)</p><p>A more detailed discussion of the approach to rabies vaccination in returning travelers is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis", section on 'Returning travelers'</a>.)</p><p class="headingAnchor" id="H3169355442"><span class="h3">Deviations from immunization regimens</span><span class="headingEndMark"> — </span>Every attempt should be made to administer post-exposure prophylaxis according to the appropriate CDC or WHO schedule, since data on effectiveness are limited to regimens that are administered using the published schedules. (See <a class="local">'Regimens for unvaccinated individuals'</a> above and <a class="local">'Regimens for previously vaccinated individuals'</a> above and <a class="local">'Resource-limited settings'</a> above.)</p><p>However, if there is a deviation from standard immunization regimens, the following approach can be used:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of doses</strong> – Deviations of a few days from the immunization schedule do not require complete reinitiating vaccination [<a href="#rid51">51</a>]. If a patient misses an injection, the immunization series should be continued until all doses have been administered according to the regular intervals (eg, if day 7 vaccine is given on day 10, the next dose should be on day 17, 7 days later, etc).</p><p></p><p class="bulletIndent1">For more significant deviations from the schedule, antibody testing using the rapid fluorescent focus inhibition test (RFFIT) should be conducted 7 to 14 days after the final dose is given [<a href="#rid4">4</a>]. Serologic testing is discussed below. (See <a class="local">'Postvaccination serologic testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>If different vaccine formulations were used</strong> – In returning travelers who need to complete a vaccine series, it is important to determine what vaccine they received abroad and the dosing schedule. Many vaccines available internationally are essentially equivalent in immunogenicity to those available in the United States and the series can be completed on schedule. If there is any question about the type of vaccine that was received, patients can typically complete the immunization series with intramuscularly administered <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> and have a follow-up titer to document appropriate response [<a href="#rid4">4</a>]. Consultation with local or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Frabies%2Fresources%2Fcontacts.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP34avy7K48jfK0PvxCnCh3r9Biz1uu56%2BYn0IY7HtcwZl6JErfqwi8KMF%2FrvK5VwQ%3D%3D&amp;TOPIC_ID=8303" target="_blank">state public health authorities</a> is recommended (elsewhere, local experts or public health authorities should be consulted). A more detailed discussion of the approach to prophylaxis in returning travelers is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis", section on 'Returning travelers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>If RIG was not administered</strong> – If a traveler sustained scratches or abrasions, WHO guidelines recommend only vaccine, which differs from CDC guidelines, which recommend both vaccine and RIG for this type of exposure (see <a class="local">'Resource-limited settings'</a> above). In this setting, RIG can be administered upon return if it is no later than seven days after the start of an immunization series; RIG should not be administered after that because RIG may suppress the immune response to <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis", section on 'Returning travelers'</a>.)</p><p></p><p class="headingAnchor" id="H29"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>There is no evidence that rabies vaccination is associated with fetal abnormalities or adverse pregnancy outcomes of any kind [<a href="#rid53">53,54</a>]. Pregnancy is therefore not a contraindication to post-exposure prophylaxis if a rabies exposure has occurred. The danger of rabies after a significant exposure far outweighs any theoretical risk from administration. For patients in a continuous or frequent risk category, pre-exposure prophylaxis might also be necessary during pregnancy.</p><p class="headingAnchor" id="H30"><span class="h3">Antimalarial prophylaxis</span><span class="headingEndMark"> — </span>Limited data show that antimalarial prophylaxis with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> may blunt the immune response to <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a>. In a randomized controlled study of 51 veterinary students, antibody responses to intradermal HDCV were assessed when chloroquine was administered [<a href="#rid55">55</a>]. Although all participants achieved an adequate vaccine response according to CDC criteria, the mean neutralizing antibody titers were lower in the 26 individuals who also received malaria prophylaxis. Decreased antibody titers have not been documented with other antimalarials (eg, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>); however, this is being studied.</p><p>The clinical significance of these findings is unclear. Although the WHO had previously recommended that patients receiving antimalarial prophylaxis be given <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> intramuscularly rather than intradermally, this recommendation was removed from its 2018 position paper on rabies vaccines [<a href="#rid11">11,12</a>]. According to the WHO, the effect of antimalarial agents on vaccine-induced neutralizing antibody is unlikely to be clinically significant.</p><p class="headingAnchor" id="H32"><span class="h2">Risk of prophylaxis failure</span><span class="headingEndMark"> — </span>Recommended post-exposure prophylaxis regimens appear uniformly effective.</p><p>Occasional case reports of rabies in vaccinated individuals have occurred and have been associated with the following deviations from currently recommended practice [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Improper wound cleaning</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate dosing of RIG</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of RIG administration in the wound site</p><p class="bulletIndent1"><span class="glyph">●</span>Vaccine administration in the gluteal area</p><p></p><p>To reduce the risk of failure, an antibody titer should be checked if a post-exposure prophylaxis regimen using unknown or nonstandard biologics was administered. (See <a class="local">'Deviations from immunization regimens'</a> above and <a class="local">'Postvaccination serologic testing'</a> below.)</p><p>If the serologic response was appropriate, no additional immunization is needed. However, if the response was not adequate, post-exposure prophylaxis should be readministered in consultation with the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Frabies%2Fresources%2Fcontacts.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP34avy7K48jfK0PvxCnCh3r9Biz1uu56%2BYn0IY7HtcwZl6JErfqwi8KMF%2FrvK5VwQ%3D%3D&amp;TOPIC_ID=8303" target="_blank">local or state public health department</a> (elsewhere, local experts or public health authorities should be consulted).</p><p class="headingAnchor" id="H1343198751"><span class="h2">Postvaccination serologic testing</span><span class="headingEndMark"> — </span>In general, routine postvaccination serologic testing is not necessary following post-exposure prophylaxis. <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">Rabies vaccine</a> induces protective neutralizing antibodies in the vast majority of patients. Questions as to whether a particular patient should have serologic testing after post-exposure prophylaxis should be directed to the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Frabies%2Fresources%2Fcontacts.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP34avy7K48jfK0PvxCnCh3r9Biz1uu56%2BYn0IY7HtcwZl6JErfqwi8KMF%2FrvK5VwQ%3D%3D&amp;TOPIC_ID=8303" target="_blank">local or state public health department</a> (elsewhere, local experts or public health authorities should be consulted).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised patients</strong> – For immunocompromised patients receiving post-exposure prophylaxis, testing should be performed 7 to 14 days after the final dose is given  (<a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who may have received inadequate prophylaxis</strong> – To assess the response to post-exposure prophylaxis in patients who may have received a regimen that provided suboptimal protection (eg, the prophylaxis regimen did not include human <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> [HRIG] or substituted equine RIG [ERIG]; the patient received any part of the post-exposure regimen in a resource-limited setting where vaccine handling and storage may have been compromised or where vaccine production was not well regulated; there were significant deviations from the vaccine schedule), testing should be performed 7 to 14 days after the final dose is given if the first titer is below 0.5 international units/mL as measured by the RFFIT. Additional doses may be needed.</p><p></p><p>Serologic testing should be performed using the rapid fluorescent focus inhibition test (RFFIT), and a titer ≥0.5 international units/mL is felt to represent an adequate response to vaccination [<a href="#rid6">6,11</a>]. In 2022, the CDC endorsed this cut-off, which matches the WHO cut-off. The CDC’s new cut-off is a more cautious value than the previous one, although no infections occurred among vaccinated individuals using the prior cut-off.</p><p>Commercially available enzyme-linked immunosorbent assay (ELISA) tests for rabies antibody are not specific to neutralizing antibodies and should not be used for testing for immunity.</p><p>For immunocompromised patients and those who may have received a suboptimal post-exposure regimen, failure to demonstrate an adequate immune response when tested may indicate the need for additional vaccination. Such patients should be managed in consultation with local or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Frabies%2Fresources%2Fcontacts.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP34avy7K48jfK0PvxCnCh3r9Biz1uu56%2BYn0IY7HtcwZl6JErfqwi8KMF%2FrvK5VwQ%3D%3D&amp;TOPIC_ID=8303" target="_blank">state public health authorities</a>.</p><p class="headingAnchor" id="H456535784"><span class="h1">ADVERSE EVENTS</span><span class="headingEndMark"> — </span>Modern rabies vaccines are inactivated and have been safely administered to persons of all ages, including pregnant people and immunocompromised persons.</p><p class="headingAnchor" id="H4140664724"><span class="h2">Adverse reactions from rabies vaccine</span><span class="headingEndMark"> — </span>Patients who receive the <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> can have a variety of adverse reactions depending upon the type they receive:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human diploid cell vaccine (HDCV)</strong> – Local reactions, including pain at the injection site, redness, swelling, and induration, have been reported in many patients [<a href="#rid56">56,57</a>]. Most are mild and resolve in a few days. Systemic reactions are less common and include mild fever, headache, dizziness, and gastrointestinal symptoms [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1">Allergic reactions can occur, and patients who develop a hypersensitivity to this vaccine can receive purified chick embryo cell vaccine (PCECV) formulation if future doses are needed. During surveillance for adverse events following HDCV immunization from 1980 to 1984, the United States Centers for Disease Control and Prevention (CDC) received reports of 108 systemic allergic reactions, ranging from hives to anaphylaxis, for a rate of approximately 11 per 10,000 vaccinees [<a href="#rid58">58</a>]. In addition, systemic hypersensitivity reactions have been reported in up to 6 percent of persons receiving a booster vaccination with HDCV following primary rabies prophylaxis [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purified chick embryo cell vaccine (PCECV)</strong> – PCECV is also associated with local reactions at the injection site [<a href="#rid60">60</a>]. A retrospective review of adverse events following immunization with PCECV was conducted using data from the Vaccine Adverse Event Reporting System (VAERS) over an eight-year period [<a href="#rid61">61</a>]. Mild side effects included headache, fever, myalgia, nausea, and weakness. Serious adverse events were uncommon (3 per 100,000 doses distributed). Hypersensitivity to PCECV is less well described [<a href="#rid60">60</a>]; however, HDCV vaccine can replace PCECV if hypersensitivity develops with the use of that product as the initial vaccine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purified Vero cell </strong><a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a><strong> (PVRV)</strong> – Like HDCV and PCECV, PVRV is associated with both local and systemic reactions [<a href="#rid62">62</a>]. In a study of 60 healthy adult volunteers who received a pre-exposure vaccine series of a new PVRV vaccine either intramuscularly or intradermally or received a previously licensed PVRV vaccine intramuscularly, 116 adverse events were reported across all three groups. Twenty-eight local reactions included pain at the injection site, erythema, pruritus, induration, and edema. All local reactions were judged to be relatively mild and resolved rapidly. Eighty-eight systemic reactions were comprised primarily of headache, arthralgia, and myalgia and were self-limited. There were no significant differences in the type of rate of reported local or system reactions between the three groups.</p><p></p><p>Rare case reports of neurologic adverse events (eg, acute disseminated encephalomyelitis, Guillain-Barré) following rabies vaccination have also been reported; however, causality has not been established [<a href="#rid4">4</a>].</p><p>Clinicians in the United States who require assistance in the management of a patient with significant hypersensitivity should contact their <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Frabies%2Fresources%2Fcontacts.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLP34avy7K48jfK0PvxCnCh3r9Biz1uu56%2BYn0IY7HtcwZl6JErfqwi8KMF%2FrvK5VwQ%3D%3D&amp;TOPIC_ID=8303" target="_blank">state health department rabies consultant</a> or the CDC. All serious vaccine reactions should be reported to VAERS, phone number 800-822-7967 or online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2F&amp;token=8m3rK0tzv73hmwLVujPJP2ExUaq%2FDfXBz50uj1EPWpI%3D&amp;TOPIC_ID=8303" target="_blank">vaers.hhs.gov</a>.</p><p>Although severe reactions are rare, one study found that approximately 50 percent of individuals receiving either pre- or post-exposure prophylaxis experienced at least one systemic reaction and that 5 percent of individuals actually discontinued the vaccine series due to their reaction. Individuals who have had a rabies exposure and who experience a systemic reaction may need to be encouraged to complete the post-exposure series [<a href="#rid63">63</a>]. Counseling patients about the possibility of such systemic reactions prior to vaccination may help manage expectations and reduce drop-out rates through the series.</p><p class="headingAnchor" id="H103160685"><span class="h2">Adverse reactions from rabies immune globulin</span><span class="headingEndMark"> — </span>Human <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> (HRIG) is associated with local reactions including pain and tenderness, erythema, and induration. Headache is the most commonly reported systemic side effect [<a href="#rid64">64</a>]. There has never been evidence of transmission of any known virus or other infectious agent by HRIG approved for use in the United States.</p><p>Use of equine <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> (ERIG) products can be associated with hypersensitivity reactions and should be administered under close medical supervision. However, most of the available preparations are associated with very few adverse reactions. The purified immunoglobulin cleavage fragment products may be less reactogenic [<a href="#rid7">7</a>].</p><p>In a retrospective study at the Thai Red Cross, adverse events to HRIG and ERIG were reviewed in more than 70,000 patients [<a href="#rid65">65</a>]. A higher number of side effects occurred among those who had received ERIG (1.83 versus 0.09 percent). General observations also included a higher risk of hypersensitivity to either product among females and a lower risk of serum sickness in children under 10 years of age. Only one patient developed anaphylaxis associated with ERIG administration.</p><p class="headingAnchor" id="H1525667136"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113373.html" rel="external">"Society guideline links: Rabies"</a>.)</p><p class="headingAnchor" id="H11516870"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82947.html" rel="external">"Patient education: Rabies (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Rabies is virtually always fatal, but infection can be prevented with proper wound care and post-exposure prophylaxis using rabies biologics (<a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a>, <a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">rabies immune globulin</a> [RIG]). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rabies biologics</strong> – Several <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> and RIG formulations are available. The proper route and sites of administration are critical to optimize the protective efficacy and prevent vaccine failure. (See <a class="local">'Rabies biologics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaccine administration</strong> – Rabies vaccines should be administered intramuscularly (IM):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In adults (ie, age ≥19 years), the deltoid muscle of the arm is the only acceptable IM site of vaccine administration.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In children 3 to 18 years old, the deltoid muscle is preferred, although the anterolateral aspect of the thigh is an acceptable alternative.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In children ≤2 years old, the anterolateral aspect of the thigh is preferred; however, in children aged 12 months to 2 years, the deltoid muscle is an acceptable alternative if the muscle mass is adequate.</p><p></p><p class="bulletIndent2">Vaccine should <strong>never</strong> be administered in the gluteal area because this may result in lower antibody titers. (See <a class="local">'Rabies vaccines'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9848" href="/z/d/drug information/9848.html" rel="external">Rabies immune globulin</a><strong> administration</strong> – If RIG is required, the wound should be infiltrated with RIG; any remaining dose should be given IM and at a different intramuscular site than the vaccine. (See <a class="local">'Rabies immune globulin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-exposure prophylaxis</strong> – Pre-exposure prophylaxis is the use of <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> to induce at least partial immunity in individuals who are at elevated risk of acquiring rabies. A detailed discussion of the indications and regimens for pre-exposure prophylaxis is found separately. (See  <a class="medical medical_review" href="/z/d/html/139471.html" rel="external">"Rabies pre-exposure prophylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-exposure prophylaxis</strong> – Post-exposure rabies prophylaxis includes proper wound care and administration of rabies biologics (ie, <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> with or without RIG) to elicit neutralizing antibodies after a rabies exposure. (See <a class="local">'Post-exposure prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – Once it has been determined that the patient should receive rabies post-exposure prophylaxis, prophylaxis should begin as soon as possible after the exposure. The decision to initiate prophylaxis requires a careful risk assessment and depends upon the type of exposure, the local rabies epidemiology, the circumstances of the exposure incident, and the availability of the animal for observation or rabies testing  (<a class="graphic graphic_algorithm graphicRef71322" href="/z/d/graphic/71322.html" rel="external">algorithm 1</a>) [<a href="#rid4">4</a>]. A detailed discussion of when to initiate rabies prophylaxis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis", section on 'Risk assessment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Post-exposure regimens</strong> – For patients who have had an exposure to rabies, we recommend post-exposure prophylaxis (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Because post-exposure prophylaxis is highly effective and rabies is a fatal infection, we give post-exposure prophylaxis to any patient who is deemed to have had a potential exposure.</p><p></p><p class="bulletIndent2">The regimen used for post-exposure prophylaxis depends upon the patient's previous immunization history and immune status.</p><p></p><p class="bulletIndent2">Dosing schedules, doses, and routes of administration are summarized in the table  (<a class="graphic graphic_table graphicRef70600" href="/z/d/graphic/70600.html" rel="external">table 2</a>) but, in certain resource-limited settings, may be modified to maximize the availability of vaccine  (<a class="graphic graphic_table graphicRef118695" href="/z/d/graphic/118695.html" rel="external">table 4</a>). (See <a class="local">'Regimens for unvaccinated individuals'</a> above and <a class="local">'Regimens for previously vaccinated individuals'</a> above and <a class="local">'Resource-limited settings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Deviations from vaccine schedule</strong> – Immunization schedules should be adhered to as closely as possible. However, if a delay of only three to four days occurs, the schedule should simply resume with intervals preserved within the new schedule. By contrast, if the dosing schedule has been significantly violated, antibody titers should be assessed to evaluate efficacy. (See <a class="local">'Deviations from immunization regimens'</a> above and <a class="local">'Postvaccination serologic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – Both rabies immunoglobulin and rabies vaccines have been associated with local reactions. In the setting of a hypersensitivity reaction to a vaccine, an alternative formulation can be used. (See <a class="local">'Adverse events'</a> above.)</p><p></p><p class="headingAnchor" id="H29251206"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Wichai Techasathit, MD, MPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis 2015; 9:e0003709.</a></li><li class="breakAll">Ma X, Bonaparte S, Toro M, et al. Rabies surveillance in the United States during 2020. J Am Vet Med Assoc 2022. Available at: https://avmajournals.avma.org/view/journals/javma/260/10/javma.22.03.0112.xml. (Accessed on June 16, 2022).</li><li><a class="nounderline abstract_t">Ma X, Bonaparte S, Toro M, et al. . Rabies surveillance in the United States during 2020. J Am Vet Med Assoc 2022; 260.</a></li><li><a class="nounderline abstract_t">Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Cost of Rabies Prevention. https://www.cdc.gov/rabies/location/usa/cost.html.</li><li><a class="nounderline abstract_t">Rao AK, Briggs D, Moore SM, et al. Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:619.</a></li><li class="breakAll">World Health Organization. WHO Expert Consultation on Rabies, second report. Geneva, 2013. WHO Technical Report Series, No. 982. http://apps.who.int/iris/bitstream/10665/85346/1/9789240690943_eng.pdf.</li><li class="breakAll">General Best Practice Guidelines for Immunization. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. (Accessed on June 16, 2022).</li><li><a class="nounderline abstract_t">Fishbein DB, Sawyer LA, Reid-Sanden FL, Weir EH. Administration of human diploid-cell rabies vaccine in the gluteal area. N Engl J Med 1988; 318:124.</a></li><li><a class="nounderline abstract_t">Wilde H, Tipkong P, Khawplod P. Economic issues in postexposure rabies treatment. J Travel Med 1999; 6:238.</a></li><li class="breakAll">World Health Organization. WHO Expert Consultation on Rabies, Third Report. http://apps.who.int/iris/bitstream/handle/10665/272364/9789241210218-eng.pdf?ua=1 (Accessed on July 17, 2018).</li><li class="breakAll">World Health Organization. Weekly epidemiological record, No 16. 20 April 2018. http://apps.who.int/iris/bitstream/handle/10665/272371/WER9316.pdf?ua=1 (Accessed on July 17, 2018).</li><li><a class="nounderline abstract_t">Hemachudha T, Phanuphak P, Johnson RT, et al. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 1987; 37:550.</a></li><li><a class="nounderline abstract_t">Chantanakajornfung A, Naraporn N, Khumphai W, et al. A study of human rabies immune globulin manufactured by the Thai Red Cross. Vaccine 1999; 17:979.</a></li><li><a class="nounderline abstract_t">Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 2017; 390:1511.</a></li><li><a class="nounderline abstract_t">Cabasso VJ, Loofbourow JC, Roby RE, Anuskiewicz W. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ 1971; 45:303.</a></li><li class="breakAll">American Academy of Pediatrics. Rabies. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd edition. Pg 626.</li><li class="breakAll">Package insert KEDRAB. https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM573307.pdf (Accessed on November 27, 2017).</li><li><a class="nounderline abstract_t">Wilde H, Khawplod P, Hemachudha T, Sitprija V. Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis 2002; 34:477.</a></li><li><a class="nounderline abstract_t">Goudsmit J, Marissen WE, Weldon WC, et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006; 193:796.</a></li><li><a class="nounderline abstract_t">Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922.</a></li><li><a class="nounderline abstract_t">Gogtay N, Thatte U, Kshirsagar N, et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine 2012; 30:7315.</a></li><li><a class="nounderline abstract_t">Gogtay NJ, Munshi R, Ashwath Narayana DH, et al. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study. Clin Infect Dis 2018; 66:387.</a></li><li class="breakAll">Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/acip/index.html (Accessed on July 02, 2021).</li><li><a class="nounderline abstract_t">DEAN DJ, BAER GM, THOMPSON WR. Studies on the local treatment of rabies-infected wounds. Bull World Health Organ 1963; 28:477.</a></li><li><a class="nounderline abstract_t">Jentes ES, Blanton JD, Johnson KJ, et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. J Travel Med 2013; 20:148.</a></li><li><a class="nounderline abstract_t">Anderson LJ, Sikes RK, Langkop CW, et al. Postexposure trial of a human diploid cell strain rabies vaccine. J Infect Dis 1980; 142:133.</a></li><li><a class="nounderline abstract_t">Strady A, Lang J, Lienard M, et al. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998; 177:1290.</a></li><li><a class="nounderline abstract_t">Mansfield KL, Andrews N, Goharriz H, et al. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans. Vaccine 2016; 34:5959.</a></li><li><a class="nounderline abstract_t">Both L, Banyard AC, van Dolleweerd C, et al. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012; 12:397.</a></li><li><a class="nounderline abstract_t">Human rabies prevention--United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1.</a></li><li><a class="nounderline abstract_t">Smith JS, Fishbein DB, Rupprecht CE, Clark K. Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 1991; 324:205.</a></li><li><a class="nounderline abstract_t">Boland TA, McGuone D, Jindal J, et al. Phylogenetic and epidemiologic evidence of multiyear incubation in human rabies. Ann Neurol 2014; 75:155.</a></li><li><a class="nounderline abstract_t">Bahmanyar M, Fayaz A, Nour-Salehi S, et al. Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976; 236:2751.</a></li><li><a class="nounderline abstract_t">Navarrete-Navarro S, Aguilar-Setién A, Avila-Figueroa C, et al. Improved serological response to human diploid cell rabies vaccine when given simultaneously with antirabies hyperimmune globulin. Arch Med Res 1999; 30:332.</a></li><li><a class="nounderline abstract_t">Bijok U, Vodopija I, Smerdel S, et al. Purified chick embryo cell (PCEC) rabies vaccine for human use: clinical trials. Behring Inst Mitt 1984; :155.</a></li><li><a class="nounderline abstract_t">Wang XJ, Lang J, Tao XR, et al. Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China. Southeast Asian J Trop Med Public Health 2000; 31:287.</a></li><li><a class="nounderline abstract_t">Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Committee on Infectious Diseases. Rabies-prevention policy update: new reduced-dose schedule. Pediatrics 2011; 127:785.</a></li><li><a class="nounderline abstract_t">Enright JB, Franti CE, Frye FL, Behymer DE. The effects of corticosteroids on rabies in mice. Can J Microbiol 1970; 16:667.</a></li><li class="breakAll">Deshpande A, Briggs DJ, Dietzschold B et al. Immune response to purified chick embryo cell vaccine (PCECV) in HIV-infected individuals in Mumbai India using a simulated rabies post-exposure regimen. In: Proceedings of the IX International Meeting on Research Advances and Rabies Control in the Americas, Puerto Vallarta Mexico, December 1998.</li><li><a class="nounderline abstract_t">Kopel E, Oren G, Sidi Y, David D. Inadequate antibody response to rabies vaccine in immunocompromised patient. Emerg Infect Dis 2012; 18:1493.</a></li><li><a class="nounderline abstract_t">Rupprecht CE, Briggs D, Brown CM, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009; 27:7141.</a></li><li><a class="nounderline abstract_t">Xu C, Lau CL, Clark J, et al. Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis. Vaccine 2021; 39:1044.</a></li><li><a class="nounderline abstract_t">Shantavasinkul P, Tantawichien T, Wilde H, et al. Postexposure rabies prophylaxis completed in 1 week: preliminary study. Clin Infect Dis 2010; 50:56.</a></li><li><a class="nounderline abstract_t">Vora NM, Clippard JR, Stobierski MG, et al. Animal bite and rabies postexposure prophylaxis reporting--United States, 2013. J Public Health Manag Pract 2015; 21:E24.</a></li><li><a class="nounderline abstract_t">Harverson G, Wasi C. Use of post-exposure intradermal rabies vaccination in a rural mission hospital. Lancet 1984; 2:313.</a></li><li><a class="nounderline abstract_t">Warrell MJ, Nicholson KG, Warrell DA, et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985; 1:1059.</a></li><li><a class="nounderline abstract_t">Chutivongse S, Wilde H, Supich C, et al. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1990; 335:896.</a></li><li><a class="nounderline abstract_t">Quiambao BP, Dimaano EM, Ambas C, et al. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005; 23:1709.</a></li><li><a class="nounderline abstract_t">Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N Engl J Med 2004; 351:2626.</a></li><li><a class="nounderline abstract_t">Khawplod P, Wilde H, Chomchey P, et al. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously? Vaccine 1996; 14:389.</a></li><li><a class="nounderline abstract_t">Chutivongse S, Wilde H, Benjavongkulchai M, et al. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clin Infect Dis 1995; 20:818.</a></li><li><a class="nounderline abstract_t">Varner MW, McGuinness GA, Galask RP. Rabies vaccination in pregnancy. Am J Obstet Gynecol 1982; 143:717.</a></li><li><a class="nounderline abstract_t">Pappaioanou M, Fishbein DB, Dreesen DW, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986; 314:280.</a></li><li><a class="nounderline abstract_t">Sabchareon A, Lang J, Attanath P, et al. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin Infect Dis 1999; 29:141.</a></li><li><a class="nounderline abstract_t">Fishbein DB, Dreesen DW, Holmes DF, et al. Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations. Vaccine 1989; 7:437.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Systemic allergic reactions following immunization with human diploid cell rabies vaccine. MMWR Morb Mortal Wkly Rep 1984; 33:185.</a></li><li><a class="nounderline abstract_t">Fishbein DB, Yenne KM, Dreesen DW, et al. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine 1993; 11:1390.</a></li><li><a class="nounderline abstract_t">Dreesen DW, Fishbein DB, Kemp DT, Brown J. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989; 7:397.</a></li><li><a class="nounderline abstract_t">Dobardzic A, Izurieta H, Woo EJ, et al. Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 2007; 25:4244.</a></li><li><a class="nounderline abstract_t">Kulkarni PS, Sapru A, D'costa PM, et al. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers. Vaccine 2013; 31:2719.</a></li><li><a class="nounderline abstract_t">Mattner F, Bitz F, Goedecke M, et al. Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients. Infection 2007; 35:219.</a></li><li><a class="nounderline abstract_t">Lang J, Gravenstein S, Briggs D, et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 1998; 26:7.</a></li><li><a class="nounderline abstract_t">Suwansrinon K, Jaijareonsup W, Wilde H, et al. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg 2007; 101:206.</a></li></ol></div><div id="topicVersionRevision">Topic 8303 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25881058" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Estimating the global burden of endemic canine rabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25881058" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Estimating the global burden of endemic canine rabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33978439" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Rabies surveillance in the United States during 2020</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496505" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496505" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35511716" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35511716" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35511716" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336395" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Administration of human diploid-cell rabies vaccine in the gluteal area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575172" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Economic issues in postexposure rabies treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575172" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Economic issues in postexposure rabies treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575172" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Economic issues in postexposure rabies treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2436091" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10067706" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A study of human rabies immune globulin manufactured by the Thai Red Cross.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28754494" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5316911" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5316911" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5316911" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11797174" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Postexposure treatment of rabies infection: can it be done without immunoglobulin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16479514" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18804136" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23010601" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020321" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020321" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14026136" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Studies on the local treatment of rabies-infected wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23577860" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7410895" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Postexposure trial of a human diploid cell strain rabies vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593014" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27997343" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541629" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Passive immunity in the prevention of rabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10077411" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Human rabies prevention--United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985241" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Unexplained rabies in three immigrants in the United States. A virologic investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24038455" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Phylogenetic and epidemiologic evidence of multiyear incubation in human rabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1036566" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573637" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Improved serological response to human diploid cell rabies vaccine when given simultaneously with antirabies hyperimmune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6395850" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Purified chick embryo cell (PCEC) rabies vaccine for human use: clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127328" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20300058" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444598" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rabies-prevention policy update: new reduced-dose schedule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4921874" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effects of corticosteroids on rabies in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4921874" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The effects of corticosteroids on rabies in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22932226" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Inadequate antibody response to rabies vaccine in immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19925944" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33478786" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995217" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Postexposure rabies prophylaxis completed in 1 week: preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25084537" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Animal bite and rabies postexposure prophylaxis reporting--United States, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6146863" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of post-exposure intradermal rabies vaccination in a rural mission hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2860284" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1969993" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Postexposure prophylaxis for rabies with antiserum and intradermal vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705476" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602023" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical practice. Prophylaxis against rabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8735549" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795079" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091247" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rabies vaccination in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510393" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433577" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2815979" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6423947" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Systemic allergic reactions following immunization with human diploid cell rabies vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8310759" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2815976" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382435" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23583817" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646909" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637744" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16806332" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sex- and age-related differences in rabies immunoglobulin hypersensitivity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
